The pipeline for developing new drugs to combat antibiotic-resistant superbugs remains alarmingly sparse, having contracted by a significant 35% over the past five years. This stark decline raises grave concerns among health experts, who predict that the annual global death toll linked to drug-resistant infections will surge to a staggering 8 million by 2050, effectively doubling current figures.
Shrinking Research and Development Efforts
According to a comprehensive report jointly published by the Access to Medicine Foundation, a Netherlands-based non-profit, and the Wellcome Trust, the number of active drug development projects from major pharmaceutical companies has plummeted from 92 to just 60 in recent years. This reduction underscores a troubling loss of momentum in industry investment, despite the escalating threat posed by antimicrobial resistance.
Jayasree K Iyer, Chief Executive of the Access to Medicine Foundation, emphasised the severity of the situation, stating that drug resistance represents the single most significant threat to global healthcare today. She highlighted that while progress is possible, the overall research and development landscape remains insufficiently robust to address the growing crisis.
Leading and Lagging Players in the Field
The report identifies the UK's GSK as a frontrunner in antimicrobial resistance research, with an impressive portfolio of 30 ongoing projects. GSK stands as one of only three large pharmaceutical firms continuing to invest substantially in this critical area. The other key contributors are Japan's Shionogi and Otsuka.
In contrast, the US drugmaker Pfizer, which previously shared the top spot with GSK in 2021, has notably scaled back its involvement. Furthermore, Britain's largest pharmaceutical company, AstraZeneca, is entirely absent from the rankings, as it maintains no antibiotic portfolio, with infectious diseases never having been a core focus for the firm.
Global Impact and Vulnerable Populations
Currently, drug-resistant infections directly cause over 1 million deaths annually and contribute to approximately 4 million fatalities worldwide each year. Both statistics are projected to double by 2050, reaching nearly 2 million and more than 8 million deaths respectively. This escalating crisis disproportionately affects individuals in low- and middle-income countries, where infectious diseases are most prevalent and healthcare resources are often limited.
The Access to Medicine Foundation has issued a urgent call to action, stressing that there is no time to lose in addressing this public health emergency. Hospitals globally have reported a disturbing increase in common infections that no longer respond to standard antibiotic treatments, exacerbating the challenge.
Recent Advances and Ongoing Challenges
Despite the overall thin pipeline, there are glimmers of hope. The report notes that three recently approved antibiotics, along with seven other promising medicines in late-stage development, demonstrate that it is feasible to gain ground in the fight against superbugs. For instance, in December, the US health regulator approved Innoviva's zoliflodacin for gonorrhoea and GSK's gepotidacin for urinary tract infections and gonorrhoea, marking the first new antibiotics for these conditions in decades.
However, the World Health Organization has reported alarming trends, indicating that one in six laboratory-confirmed bacterial infections were resistant to antibiotics in 2023. Additionally, more than 40% of antibiotics have lost effectiveness against common blood, gut, urinary tract, and sexually transmitted infections between 2018 and 2023, highlighting the rapid pace of resistance development.
The report assesses the efforts of 25 companies, including seven large research-based firms, ten generic medicine manufacturers, and eight smaller biotech developers. This broad evaluation underscores the need for a concerted, multi-faceted approach to reinvigorate the antibiotic pipeline and safeguard global health against the relentless advance of drug-resistant superbugs.
